Karen Firestone bought $51k of AMLX
director at Amylyx Pharmaceuticals, Inc.. 3,800 shares at an average of $13.51, traded May 21, 2026, filed May 26, 2026.
Score components
- +15RoleDirector
- +7Trade size$51k at market
- +3Relative to holdingsHoldings up 6%
- +4Price context24% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-239216, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 21, 2026 | POpen-market purchase Common Stock | +3,800 | $13.51 | $51k | 66,900 | May 26, 2026 |
Related signals
Other insiders at Amylyx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | Amylyx Pharmaceuticals, Inc. | George M Milne Jr director | $831k 30,000 shares | -4% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Justin B. Klee Co-Chief Executive Officer | $980k 30,464 shares | -1% | |
| 65Notable | Amylyx Pharmaceuticals, Inc. | Joshua B Cohen Co-Chief Executive Officer | $981k 30,464 shares | -1% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $310k 9,536 shares | -5% | |
| 52Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $350k 10,810 shares | -4% | |
| 44Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $325k 10,028 shares | -3% | |
| 19Weak | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $539k 30,000 shares | -14% | |
| 40Moderate | Amylyx Pharmaceuticals, Inc. | Gina Mazzariello Chief Legal Officer | $99k 6,844 shares | -5% | |
| 47Moderate | Amylyx Pharmaceuticals, Inc. | James M Frates Chief Financial Officer | $115k 7,909 shares | -5% | |
| 40Moderate | Amylyx Pharmaceuticals, Inc. | Camille L Bedrosian Chief Medical Officer | $94k 6,461 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.